Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $3.00 price target on the stock, down previously from $4.00.
Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events [Yahoo! Finance]
Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics [Yahoo! Finance]